Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Eyyup, Cavdar"'
Autor:
Nebi Serkan Demirci, Eyyup Cavdar, Nuriye Yildirim Ozdemir, Sinemis Yuksel, Yakup Iriagac, Gokmen Umut Erdem, Hatice Odabas, Ilhan Hacibekiroglu, Mustafa Karaagac, Mahmut Ucar, Banu Ozturk, Yakup Bozkaya
Publikováno v:
Medicina, Vol 60, Iss 5, p 818 (2024)
Background and Objectives: In ampullary cancer, 5-year survival rates are 30–50%, even with optimal resection and perioperative systemic therapies. We sought to determine the important clinicopathological features and adjuvant treatments in terms o
Externí odkaz:
https://doaj.org/article/8626dfe6c0064ba792f099060c6a66fb
Publikováno v:
Haseki Tıp Bülteni, Vol 61, Iss 1, Pp 59-68 (2023)
Aim:Complementary therapies are being increasingly preferred in patients receiving anticancer therapy to strengthen the effect of chemotherapy and control cancer-related symptoms. In this study, we investigated the prevalence of complementary therapy
Externí odkaz:
https://doaj.org/article/df101f3f96f84737893f9262ee1a5019
Publikováno v:
Iberoamerican Journal of Medicine, Vol 4, Iss 4, Pp 191-198 (2022)
Introduction: Trastuzumab emtansine (T-DM1) is one of the effective treatment options in human epidermal growth factor receptor 2 (HER2) positive breast cancer patients. In this study, we aimed to find the effect of T-DM1 on survival, its tolerabilit
Externí odkaz:
https://doaj.org/article/4db79f16413e4d81b97ea1819d6debea
Autor:
Yakup, IRIAGAC1 yakupiriagac@hotmail.com, Eyyup, CAVDAR1, Kubilay, KARABOYUN1, Okan, AVCI1, Ozkan, ALAN1, Halil, TASKAYNATAN1, Aliye, CELIKKOL1, Sonat Pinar, KARA1, Berna, ERDAL1, Erdogan Selcuk, SEBER1
Publikováno v:
Bratislava Medical Journal / Bratislavské Lekárske Listy. 2022, Vol. 123 Issue 6, p401-407. 7p.
Publikováno v:
Journal of Geriatric Oncology. 13:821-827
In older patients with cancer, it is very important to choose the appropriate treatment because they are at high risk for chemotherapy toxicity. Our study investigated characteristics of Cancer and Aging Research Group (CARG), Geriatric 8 (G8), and V
Autor:
Kubilay Karaboyun, Eyyup Cavdar, Yakup Irıagac, Abdussamet Celebı, Tanju Kapagan, Ilkay Gulturk, Ozden Demır, Okan Avcı, Erdogan Selcuk Seber
Publikováno v:
Supportive Care in Cancer. 31
Autor:
Yakup Iriagac, Eyyup Cavdar, Kubilay Karaboyun, SeherYildiz Tacar, FatmaNihan Akkoc Mustafayev, Emir Celik, Okan Avci, SadiKerem Okutur, Lokman Koral, NebiSerkan Demirci, Alpaslan Ozgun, ErdoganSelcuk Seber
Publikováno v:
Journal of Cancer Research and Therapeutics.
Autor:
Pınar Gürsoy, Ali Murat Tatlı, Dilek Erdem, Erdem Goker, Emir Çelik, Nebi Serkan Demirci, Abdullah Sakin, Muhammed Mustafa Atçı, Ertuğrul Bayram, Tuğba Akın Telli, Burak Bilgin, Ahmet Bilici, Baran Akagündüz, Sevinç Ballı, Ahmet Demirkazık, Fatıh Selcukbiricik, Serkan Menekşe, Eyyup Cavdar, Akın Öztürk, Esma Türkmen Bekmez, Serdal Turhal, Saadettin Kılıçkap, Hasan Çağrı Yıldırım, Başak Oyan, Asude Aksoy, Fatma Paksoy TURKOZ, Engin Kut, Nuran Katgı, Teoman Sakalar, Murat Akyol, Halil İbrahim Ellez, Atakan Topcu, Atike Pınar Erdoğan, Kezban Nur Pilancı, Engin Hedem, Hacı Arak, Nadiye Akdeniz, Özkan Alan, Burcu Yapar, Deniz Nart, Perran Fulden Yumuk
Objectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC).Materials and Methods We retrospectively evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::329a68f8f25bf40e2889df2b77c8165a
https://doi.org/10.21203/rs.3.rs-1125056/v1
https://doi.org/10.21203/rs.3.rs-1125056/v1